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There is great variability in the degree to which children with attention deficit/hyperactivity disorder
(ADHD) improve through behavioral treatments. This study investigates the influence of the dopamine
transporter gene (SCL6A3/DAT1) on outcome of behavioral parent training (BPT). Study subjects were
a subsample (n  50, for whom DAT1 genotypes were available) of a randomized controlled BPT
effectiveness study (N 94) comparing BPT plus ongoing routine clinical care (RCC) versus RCC alone
in referred children (4–12 years old) with ADHD. Treatment outcome was based on parent-reported
ADHD symptoms and behavioral problems. Presence of 2 versus no or 1 DAT1 10-repeat allele served
as moderator variable. Time  Treatment  Genotype effect was analyzed with repeated-measures
analysis of variance, controlling for baseline medication status. Results indicate that DAT1 moderated
treatment response (p  .009). In children with no or 1 DAT1 10-repeat allele, superior treatment effects
of BPT  RCC compared with RCC alone were present (p  .005), which was not the case in children
with 2 DAT1 10-repeat alleles (p  .57). Our findings suggest that genetic differences in DAT1 in
children with ADHD influence their susceptibility to a behavioral intervention directed at shaping their
environment through their parents. The role of the dopamine system in motivation and learning and in
the aberrant sensitivity to reinforcement in children with ADHD may explain this moderating effect,
given that the management of contingencies is typically addressed in BPT.
Keywords: ADHD, parent training, dopamine transporter gene, moderator, randomized controlled trial
Although a number of studies have provided evidence for the
efficacy of behavioral parent training (BPT) as a treatment for
children with attention-deficit/hyperactivity disorder (ADHD; for
an overview of the available evidence, see National Collaborating
Centre for Mental Health, 2009), there remains great variability in
the degree to which children with ADHD improve through behav-
ioral treatments. Several factors associated with response to be-
havioral treatments in ADHD have been identified, including
presence of comorbidity, parental depression, and socioeconomic
variables (for an overview, see Hinshaw, 2007). However, virtu-
ally nothing is known about the possible association of genetic
factors with response to psychosocial interventions. This is sur-
prising, given the growing evidence of the role of gene–
environment interactions in the etiology of ADHD and associated
behavioral problems (Thapar, Harold, Rice, Langley, &
O’Donovan, 2007; Thapar, Langley, Asherson, & Gill, 2007). BPT
can be seen as an intervention that particularly focuses on the
child’s environment. It may well be the case that genetic factors
play a role in the child’s susceptibility to interventions that are
directed at changing his or her environment in a positive way. A
theoretical framework for this hypothesis is provided by Belsky’s
differential susceptibility perspective (see Belsky & Pluess, 2009;
Belsky, Bakermans-Kranenburg, & Van IJzendoorn, 2007; Ellis,
Boyce, Belsky, Bakermans-Kranenburg, & Van IJzendoorn,
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2011), which particularly stresses that some individuals are more
susceptible than others to both negative and positive environmen-
tal influences, with specific moderating genes that seem to func-
tion as plasticity factors (for an overview, see Belsky & Pluess,
2009).
To our knowledge, only one study has examined the interaction
between genetic factors and response to behavioral treatment
(Bakermans-Kranenburg, Van IJzendoorn, Pijlman, Mesman, &
Juffer, 2008). That study investigated the role of dopamine recep-
tor D4 (DRD4) polymorphisms in explaining differential effects of
a behavioral parent treatment in preschool children with external-
izing behavior problems. Results indicated that children with the
DRD4 seven-repeat allele showed larger intervention effects at
1-year follow-up than did children without the DRD4 seven-repeat
allele. Treatment effects were particularly large in children with
the DRD4 seven-repeat allele whose parents showed the largest
increase in positive discipline.
In contrast to the scarcity of studies on genetic susceptibility to
behavioral interventions stands the growing interest in identifying
genetic polymorphisms associated with stimulant medication re-
sponse (i.e., pharmacogenetic studies). The studies in that area
have largely focused on dopamine-related genes, on the basis of
the notion that stimulant medications affect dopamine release or
reuptake through blockade of the dopamine transporter, thus lead-
ing to increased synaptic dopamine (Thapar, O’Donovan, & Owen,
2005; Volkow & Swanson, 2003; Volkow, Fowler, Wang, &
Swanson, 2004). With respect to the genes that have been exam-
ined in association with methylphenidate response (for an over-
view, see McGough, 2005), the most evidence is available for the
dopamine transporter gene (DAT1 40bp variable number of tan-
dem repeats). However, until now, findings have been equivocal
(McGough, 2005), with some studies pointing to an association of
homozygosity of the 10-repeat allele (Roman, Rohde, & Hutz,
2004; Winsberg & Comings, 1999) and others of homozygosity of
the nine-repeat allele (Joober et al., 2007; Stein et al., 2005) and
poor response to methylphenidate.
It could be hypothesized that DAT1 is also associated with
response to BPT. The dopamine transporter has a crucial role in
regulating the extracellular midbrain dopamine level in the ventral
tegmental area and substantia nigra, which modulate a wide variety
of functions, including motivation, attention, reward, learning, and
operant conditioning (Ettenberg, 1989; Le Moal, 1995; Schultz,
1997, 2001, 2006; Waelti, Dickinson, & Schultz, 2001). Particu-
larly operant conditioning is the central mechanism through which
BPT programs appear to work (Berkowitz & Graziano, 1972).
Reinforcement is one of the main interventions in BPT, whereas
several findings support the suggestion that children with ADHD
are aberrantly sensitive to reinforcement (for a review, see Luman,
Oosterlaan, & Sergeant, 2005); for example, children with ADHD
prefer immediate over delayed rewards (Rapport, Tucker, DuPaul,
Merlo, & Stoner, 1986; Sonuga-Barke, Taylor, Sembi, & Smith,
1992; Tripp & Alsop, 2001) and need more frequent and intensive
reinforcement to increase their task performance and motivation
level (Haenlein & Caul, 1987). These reward contingencies are
typically addressed in BPT.
Our aim in the present pilot study was to examine whether
DAT1 polymorphisms are associated with BPT treatment response
in children with ADHD. We conducted our study as a post hoc,
secondary, pilot analysis within a previously conducted random-
ized controlled treatment outcome study (Van den Hoofdakker et
al., 2007). In that study, our primary goal was to investigate the
effectiveness of a 12-session BPT group program targeting both
behavioral problems and ADHD symptoms for parents of referred
children with ADHD versus ongoing routine clinical care (RCC).
We found that a treatment program that incorporated both BPT and
RCC (BPT  RCC) was superior in reducing behavioral (opposi-
tional) problems compared with treatment with ongoing RCC
alone, whereas ADHD symptoms decreased over time regardless
of treatment group. Children’s medication status at baseline did not
affect outcome. Also, treatment allocation did not appear to affect
medication status posttreatment, other than that children allocated




The 50 children who participated in the present study came from
a larger sample of 94 referred children with ADHD whose parents
had participated in a randomized controlled treatment study (Van
den Hoofdakker et al., 2007), which examined the effectiveness of
BPT  RCC compared with RCC alone.
About two years after finishing the treatment study, we con-
tacted families to ask them to participate in the current study, that
is, to provide children’s DNA. We tried to approach all 94 fami-
lies, by mail and, in cases of nonresponse, by telephone. This
resulted in 59 families who gave informed consent (in line with
Dutch medical-ethical regulations) to collect DNA and 35 families
who did not participate. These 35 families included 17 families
who refused to participate and 18 families who did not respond at
all or who initially agreed to participate but did not return DNA.
DNA was of insufficient quality for DAT1 genotyping in nine of
the 59 children, resulting in 50 children for whom DAT1 genotyp-
ings were available.
Child and family characteristics of the children participating in
the current genetic study are given in Table 1. No statistically
significant differences in age, IQ, sex, baseline medication status,
comorbidity, ethnicity, and parental education level (examined
through univariate analyses of variance [ANOVAs] in the case of
continuous variables and chi-square tests in the case of dichoto-
mous variables) were present between participants and nonpartic-
ipants in the genetic study.
Procedure of the Treatment Study
To be eligible for the treatment study, children had to meet
Diagnostic and Statistical Manual of Mental Disorders (4th ed.;
DSM–IV; American Psychiatric Association, 1994) criteria for
ADHD, as assessed by the Dutch parent version of the Diagnostic
Interview Schedule for Children—IV (Shaffer, Fisher, Lucas, Dul-
can, & Schwab-Stone, 2000), with or without comorbid disorders.
The treatment study involved either parents who preferred behav-
ioral treatment over medication as a first line of ADHD treatment
or parents of children who still had behavioral problems despite
medication treatment, that is, if medication was (partially) ineffec-
tive or had to be stopped because of side effects. Other inclusion
criteria for the treatment study were an IQ above 80 and age
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between 4 and 12 years. Parents who had already received inten-
sive BPT the year before or had problems that required immediate
intervention (e.g., crisis in the family) were excluded.
On referral, families received routine intake assessments and
were subsequently offered RCC by a child psychiatrist or a super-
vised trainee. If parents still reported behavioral problems after this
first phase of RCC, BPT was offered and the parents were asked
to participate in the treatment study. After written informed con-
sent was provided by the parents, subjects were randomly assigned
to either BPT plus ongoing RCC (n  47) or RCC alone (n  47).
Parents in the latter condition were placed on a waiting list for
BPT. A detailed description of recruitment strategies, patient se-
lection, and demographic variables of that sample is available in
Van den Hoofdakker et al. (2007).
Treatments
BPT was delivered by experienced psychologists in twelve 2-hr
group sessions spread over 5 months, with six children’s parents
per group. The program included information about the nature of
ADHD; cognitive restructuring of parental cognitions; and behav-
ioral management techniques such as structuring the environment,
setting rules, giving commands, anticipating misbehaviors, rein-
forcing positive behaviors, ignoring, using punishment, and im-
plementing token systems. Reinforcement of positive behaviors
through praise and rewards played a major role in the BPT pro-
gram. This parental skill was introduced in Session 3 and rehearsed
in all following sessions. Parents were trained to praise and reward
prosocial behaviors immediately, that is, without delay, and with
high frequency, intensity, and consistency.
Problem behaviors that were addressed in the training were
individualized for each child, as were most of the homework
assignments. More details about the BPT treatment, therapists, and
treatment integrity are available in Van den Hoofdakker et al.
(2007). A more detailed description of the BPT manual can be
obtained from Barbara J. van den Hoofdakker.
RCC in both treatment groups was delivered by four experi-
enced child psychiatrists; could include family counseling, addi-
tive psychoeducation, and advice; and had no restrictions on the
use of pharmacotherapy. Contacts could be by telephone or face-
to-face appointments. Except for routine medication checkups,
which were usually scheduled every 3–6 months, parents were free
to get in touch with their child psychiatrist whenever they felt this
was necessary.
Collection of DNA
Buccal smears were collected using cervical brushes, stored in
buffer containing proteinase K and sodium dodecylsulfate, and
sent to the laboratory by mail. Samples were stored at 4 °C until
the DNA was isolated. DNA was isolated using salt extraction
followed by isopropanol precipitation.
Genotyping
DAT1 variable number of tandem repeats were analyzed using
polymerase chain reaction (PCR) after fragment analysis. PCR was
Table 1
Child and Family Characteristics of the Study Participants (N  50)
Characteristic
DATI
Total group Two 10-repeat alleles No or one 10-repeat allele
Age in years, M (SD) 7.6 (1.8) 7.7 (2.0) 7.5 (1.5)
Range 4.6–11.6 4.6–11.6 4.9–10.2
Total IQ, M (SD) 97.9 (11.3) 95.6 (11.4) 100.6 (10.9)
Range 82–125 82–125 83–120
Male, number (%) 44 (88.0) 24 (88.9) 20 (87.0)
On medication at baseline,a number (%) 24 (48.0) 15 (55.6) 9 (39.1)
Comorbid disorders,b number (%)
Oppositional defiant disorder 37 (74.0) 20 (74.1) 17 (73.9)
Conduct disorder 7 (14.0) 3 (11.1) 4 (17.4)
Anxiety disorder 19 (38.0) 13 (48.1) 6 (26.1)
Depressive disorder 4 (8.0) 1 (3.7) 3 (13.0)
Tic disorder 10 (20.0) 7 (25.9) 3 (13.0)
Elimination disorder 13 (26.0) 8 (29.6) 5 (21.7)
Ethnicity, number (%)
Caucasian 47 (94.0) 24 (88.9) 23 (100.0)
Other 3 (6.0) 3 (11.1) 0 (0)
Parental education level,c number (%)
Unknown 1 (2.0) 0 (0.0) 1 (4.3)
Low 16 (32.0) 9 (33.3) 7 (30.4)
Middle 19 (38.0) 12 (44.4) 7 (30.4)
High 14 (28.0) 6 (22.2) 8 (34.8)
Note. BPT  behavioral parent training; RCC  routine clinical care; DAT1  dopamine transporter gene.
a Subjects were taking primarily (87.5%) stimulants, with an average dose of methylphenidate of 19.9 mg/day; nine children in the BPT  RCC group and
15 children in the RCC alone group were on medication at study entry. b Comorbid disorders were assessed by the parent version of the Diagnostic
Interview Schedule for Children—IV (Shaffer et al., 2000). c Coding of parental education level was based on maternal education level in single-parent
families and on paternal education level in all other cases.
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performed under standard reaction conditions using a
6-carboxyfluorescein (FAM)-labeled forward primer (FAM 5-
TGT GGT GTA GGG AAC GGC CTG AG-3) and a reverse
primer (5-CTT CCT GGA GGT CAC GGC TCA AGG-3; Kirley
et al., 2002). We performed 35 cycles of denaturation (95 °C, 30 s),
annealing (65 °C, 30 s), and extension (72 °C, 1 min), followed by
a final extension step of 10 min at 72 °C. The resulting PCR
products were separated using capillary electrophoresis (ABI 3130
analyzer; Applied Biosystems, Nieuwerkerk aan den IJssel, the
Netherlands), and fragment sizes were estimated using ABI Prism
GeneMapper (2002) software. Fragments of 360, 400, 440, 480,
and 520 base pairs correspond to seven, eight, nine, 10, and 11
repeats, respectively. Our sample consisted of two DAT1 9/9-, 21
DAT1 9/10-, and 27 DAT1 10/10-repeat allele individuals. This
genotype distribution was consistent with Hardy–Weinberg equi-
librium (the expected respective numbers of individuals was 27.4,
18.8, and three, respectively; the 9-repeat allele frequency of 0.25
was 2  0.68, p  .41). Children were subdivided into two
groups: DAT1 10-repeat allele homozygote subjects (n  27)
versus subjects with one or no 10-repeat allele (n  23). This
division was based on a previous study showing that presence of
two DAT1 alleles is associated with ADHD symptoms and re-
sponse inhibition (Cornish et al., 2005).
Outcome Measures
For moderator analyses, a composite may be the preferred
outcome measure in that it more validly captures treatment out-
come in a single measure, compared with a range of separate
measures (Conners et al., 2001), especially considering the fact
that a distinction between ADHD target symptoms and behavioral
problems is not explicitly made within the BPT treatment. There-
fore, as our primary outcome measure, we used a composite score
constructed from rating scales that cover the primary targets of the
BPT program: behavioral problems and ADHD symptoms.
The composite score was derived from three parent-based out-
come measures, that is, the ADHD index subscale of the Conners’
Parent Rating Scale—Revised: Short Form (CPRS–R:S; Conners,
2001), the Externalizing scale of the Child Behavior Checklist
(CBCL; Achenbach, 1991), and occurrence and severity of five
individually chosen target problems. The target problems were
assessed with short telephone interviews (for details, see Van den
Hoofdakker et al., 2007). Examples of target problems include
being noncompliant, arguing or discussing, displaying aggression
against others, being easily and often angry, not finishing tasks, not
playing on his or her own, and crying easily. Respective Pearson
correlation coefficients between the three measures were .12
(ADHD index and individual target problems), .34 (CBCL Exter-
nalizing and individual target problems), and .48 (CBCL Exter-
nalizing and ADHD index). These intercorrelations are medium to
small, indicating some relation but also some specific variance.
Following the procedure described in Rosenthal and Rosnow
(1991), we computed the composite score by averaging the z
scores of each of the three instruments over the two assessments at
Time 1 (T1) and Time 2 (T2), thus giving equal weight to the three
outcome measures.
The CPRS–R:S and CBCL were filled in by the primary care-
giver, in all cases the mothers; the individual target problems were
evaluated through 1–2 min daily telephone calls with one of the
parents on 10 consecutive school days. In these phone calls, one of
the parents was asked by a trained psychologist, in a neutral way,
if any of the target behaviors had occurred during the past 24 hr.
If the answer was yes, he or she was asked to rate the severity of
each observed target behavior on a 5-point scale ranging from 1 
not severe to 5  exceptionally severe.
Given that some studies into the efficacy of BPT for children
with ADHD demonstrated improvement in ADHD symptoms
(e.g., Anastopoulos, Shelton, DuPaul, & Guevremont, 1993;
Sonuga-Barke et al., 2002), whereas others showed effects on
behavioral problems (e.g., Bor, Sanders, & Markie-Dadds, 2002;
Pisterman et al., 1992), we also investigated the role of DAT1
genotype specifically on improvement of behavior problems ver-
sus ADHD symptoms. For this aim, we used the ADHD index of
the CPRS–R:S, the CBCL Externalizing scale, and the assessment
of the five individually chosen target problems as separate, sec-
ondary outcome measures.
We assessed all measures at two time points: T1 and T2,
directly before the start of BPT or continued RCC (T1), and
again directly after the BPT or ongoing RCC (T2), approxi-
mately 20 weeks after T1.
Statistical Analyses
The subjects were analyzed on an intention-to-treat basis. For
two subjects, composite measure data at T2 were partially missing.
We used the last observation carried forward technique to replace
missing data at T2.
We assessed the statistical significance of the effects of time, of
Time  Treatment Group, and of Time  Treatment Group 
DAT1 Genotype (i.e., presence of two vs. no or one DAT1 10-
repeat allele) by examining the interaction Fs, using repeated
measures (mixed) ANOVAs. The composite measure was entered
as the dependent variable, with time points T1 and T2, whereas
treatment group and DAT1 genotype were subsequently included
as between-subjects factors. Medication status (i.e., presence or
absence of baseline psychotropic medication) was included as a
covariate to control for possible confounding effects of medica-
tion. Finally, the analyses of the effects of Time  Treatment
Group  DAT1 Genotype were repeated with the ADHD index of
the CPRS–R:S, the CBCL Externalizing scale, and the assessment
of five individually chosen target problems as outcome measures.
We used an alpha level of .05 to indicate statistical significance.
In the case of a significant interaction effect between treatment and
DAT1 genotype, we conducted a repeated-measures ANOVA in
the genetic subgroups separately to further analyze treatment ef-
fects and to investigate the direction of the interaction effect. Pre-
and posttreatment effect sizes (Cohen’s d) in the four sub-
groups—2 (genotypes)  2 (treatment groups)—as well as effect
sizes regarding the difference between the effects of the RCC 
BPT over the RCC treatment in the two genotype groups were
calculated by dividing the difference in the mean (difference)
scores at T1 and T2 by the pooled standard deviation (Rosnow &
Rosenthal, 1996).
Results
The results of the repeated-measures ANOVA examining ef-
fects of time, of Time  Treatment Group, and of Time 
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Treatment Group  DAT1 Genotype on our primary outcome
measure are presented in Table 2. The findings in Table 2 indicate
that effects of time and Time Treatment Group were statistically
significant, which is in line with our earlier findings (Van den
Hoofdakker et al., 2007, 2010). In addition, a statistically signif-
icant interaction effect between time, treatment group, and DAT1
genotype was present.
Results of the repeated-measures ANOVA in the children car-
rying two DAT1 10-repeat alleles, F(1, 25)  0.336, p  .568,
indicate no significant outcome difference between the two treat-
ment arms. Pre- and posttreatment effect sizes for the different
genotypes and treatment groups are given in Table 2, and findings
are illustrated in Figure 1A.
In contrast, results of the repeated-measures ANOVA in the
subgroup of children carrying one or no DAT1 10-repeat allele,
F(1, 21)  9.722, p  .005, indicate a significant outcome differ-
ence between the two treatment arms, in favor of the BPT  RCC
group. Pre- and posttreatment effect sizes for the different geno-
types and treatment groups are given in Table 2; in Figure 1B, an
illustration of the findings is presented. Effect sizes regarding the
difference between the effects of the RCC  BPT over the RCC
treatment were 0.21 for the DAT1 10-repeat homozygotes and 1.25
for the children with no or one DAT1 10-repeat allele.
The results of the analyses on the role of DAT1 genotype
specifically on improvement of behavior problems versus ADHD
symptoms were statistically significant for the five individually
chosen target problems, F(1, 48)  6.494, p  .014, and ap-
proached significance for the CBCL Externalizing scale, F(1,
48)  3.637, p  .063, and—to a lesser extent—for the ADHD
index of the CPRS–R:S, F(1, 48)  2.770, p  .103.
Discussion
There is great variability in the degree in which children with
ADHD improve through pharmacological and behavioral treat-
ments. In contrast to the growing interest in the interaction be-
tween medication response and genetic factors in children with
ADHD, the area of possible associations between behavioral treat-
ment response and genes remains understudied, despite the large
potential future impact on clinical decision making of insights into
these interactions. Our aim in the present pilot study was to
investigate the interaction between children’s DAT1 genotype
(presence of two vs. no or one DAT1 10-repeat allele) and response
to BPT in children with ADHD.
We found that DAT1 moderated treatment response: In children
with two DAT1 10-repeat alleles, no differences between BPT 
RCC and RCC alone were apparent, as opposed to the results with
the children with no or one DAT1 10-repeat allele. Only in the
latter group was BPT  RCC more effective than RCC alone.
These findings suggest that genetic differences in DAT1 in chil-
dren with ADHD play a role in their susceptibility to a behavioral
intervention directed at shaping and enriching their environment
through their parents. Thus, DAT1 polymorphisms may be a can-
didate plasticity factor of children with ADHD, determining sus-
ceptibility to both negative and positive environmental influences,
in line with the differential-susceptibility perspective conceptual-
ized by Belsky (Belsky & Pluess, 2009; Belsky, Bakermans-
Kranenburg, & van IJzendoorn, 2007; Boyce & Ellis, 2005; Ellis
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the effects of negative environmental factors in relation to DAT1
genotype.
The role of the dopamine system in motivation and learning
(Ettenberg, 1989; Schultz, 1997, 2001, 2006; Waelti et al., 2001)
and in the aberrant sensitivity to reinforcement in children with
ADHD (for a review, see Luman et al., 2005) may explain the
moderating role of a dopamine-related genetic polymorphism in
response to BPT. Children with ADHD often have motivation
problems when reinforcement is not readily available (Luman,
Oosterlaan, & Sergeant, 2008), and continuous and immediate
reinforcement appears to be effective (Haenlein & Caul, 1987).
Furthermore, children with ADHD may be sensitive to the fre-
quency but unaware of the magnitude of punishments (Luman,
Oosterlaan, Knol, & Sergeant, 2008). The management of contin-
gencies is typically addressed in BPT, in which parents learn how
to praise (immediately and with high intensity) and how to punish.
It is possible that one genetic subgroup of children with ADHD
(i.e., children with no or one DAT1 10-repeat allele) is more
sensitive to this parental approach, whereas the other subgroup
(i.e., homozygote DAT1 10-repeat children) may be less suscepti-
ble to changes in their environment. More evidence for genetically
based differences in sensitivity to family environment has recently
been demonstrated by Sonuga-Barke et al. (2009), who found that
sensitivity to the effects of positive maternal expressed emotion
was moderated by dopamine and serotonin transporter genotypes.
In this study, a reduced sensitivity to positive maternal expressed
emotion was seen in homozygote DAT1 10-repeat children, which
is clearly in line with the findings in our study.
Inherent to the character of our pilot study is the low number of
participants. Clearly, future studies with larger sample sizes are
warranted, either through newly designed studies or by collecting
DNA on previously conducted treatment outcome studies, first to
replicate our findings and second to throw more light on possible
pathways of the differential treatment response in children with
different polymorphisms of DAT1. How parenting behaviors in-
teract with the suggested genetically determined differences in
sensitivity to environmental differences of the child and why it
appears that DAT1 moderates response to BPT should be investi-
gated and currently remains unclear. Studies with larger sample
sizes would also allow researchers to examine other genetic sub-
groups (e.g., DAT1 9-repeat allele homozygote children). Further-
more, the possible involvement of other dopamine-related genes
(including DRD4 and DRD2) deserves further investigation (see
Bakermans-Kranenburg & Van IJzendoorn, 2011). Moreover, fu-
ture studies should include multiple informants, including teach-
ers, rather than the parents alone. Finally, larger scale studies could
more thoroughly investigate the effect of genotype on different
outcome measures; the current findings suggest somewhat more
specific effects of DAT1 genotype on improvement of behavior
problems than of ADHD symptoms.
Some factors regarding the representativeness of our sample in
this study need to be considered. First, we included children whose
parents still reported behavioral problems after a first phase of
RCC. Second, even if we investigated BPT treatment as an adjunct
to possible pharmacotherapy, many children may not have been
properly medicated. Although it would certainly be worthwhile for
researchers conducting future studies to investigate the effective-
ness of BPT after an optimal medication regime, the design of the
present study may have had more ecological validity. Finally,
although representative of our region and mental health clinic but
in contrast to other ADHD treatment study samples (e.g., MTA
Cooperative Group, 1999), our study included mainly participants
of White origin and from two-parent families.
In conclusion, this is the first study that examined the interaction
between DAT1 and response to BPT, showing that DAT1 poly-
morphisms moderate treatment response. This finding is intrigu-
ing, given the growing awareness that ADHD is caused by a
complex interplay between genetic and environmental risk factors
(Biederman & Faraone, 2005; Thapar, Harold, et al., 2007; Thapar,



































Figure 1. Differential treatment effects of BPT in (A) children with two 10-repeat DAT1 alleles versus (B)
children with no or one 10-repeat allele. DAT1  dopamine transporter gene; BPT  behavioral parent training;
RCC routine clinical care; T1 pretreatment score on the composite measure (severity of problem behaviors);
T2  posttreatment score on the composite measure (severity of problem behaviors).
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transporter genotypes may moderate sensitivity to family environ-
ment in children with ADHD (Sonuga-Barke et al., 2009). BPT
aims to improve parenting behavior, thus addressing an important
aspect of the child’s environment.
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